Endometrial Carcinoma and Precursors: Diagnosis and Treatment

Publication
Article
OncologyONCOLOGY Vol 14 No 1
Volume 14
Issue 1

This clinically oriented text focuses on the diagnosis and management of endometrial adenocarcinoma and endometrial hyperplasia. Due to its clinical orientation, the book does not include information on the molecular basis of endometrial cancer.

This clinically oriented text focuses on the diagnosis and management of endometrial adenocarcinoma and endometrial hyperplasia. Due to its clinical orientation, the book does not include information on the molecular basis of endometrial cancer.

At 288 pages, the book is relatively short but is strengthened by the liberal inclusion of tables, figures, histopathology photomicrographs, and other useful photographs. Although the book is generally well written in a fairly uniform fashion, there are areas of unnecessary repetition.

The first chapter centers on the epidemiology of endometrial carcinoma. Although concise, this chapter adds little new information to other published chapters on the topic. Few of the references were published later than 1994. Also, the chapter provides no discussion on inherited cancer syndromes that place a woman at higher risk of endometrial cancer.

The second chapter focuses on methods of early diagnosis and potential methods of screening women for endometrial cancer. It contains 42 excellent illustrations of endometrial pathology noted at hysteroscopy.

The third chapter reviews endocrine aspects of the uterus as they relate to endometrial cancer. It starts out with a nice overview of endometrial anatomy and physiology. There is very little discussion of the effects of tamoxifen (Nolvadex) on the uterus, however, and no mention of the effects of raloxifene (Evista). Another blatant omission is any discussion of the hormonal therapy of advanced endometrial adenocarcinoma. Also missing is advice on how to manage young women with grade 1 endometrial adenocarcinoma who wish to maintain fertility.

Chapters 4 and 5 deal with the pathology of endometrial hyperplasia and endometrial adenocarcinoma, respectively. The author presents a nice discussion of biological prognostic indicators. The chapter contains over 40 excellent photomicrographs but no gross histopathology photographs.

Chapter 6 describes treatment modalities for endometrial hyperplasia. The authors suggest the use of endometrial ablation as an alternative treatment for medically resistant forms of endometrial hyperplasia (without cytologic atypia), and devote a significant portion of the chapter to a discussion of various methods of performing ablation. This discussion seems out of place since most authorities agree that endometrial cancer and its precursors should not be treated with endometrial ablation.

Chapters 7 and 8, which cover staging and prognostic factors in endometrial carcinoma, respectively, could have been combined into one chapter. Overall, these discussions are thorough and very good.

Chapters 9 and 10 focus on the surgical management of endometrial cancer, with a nice discussion of the use of laparoscopy.

Chapter 11, which explores the role of radiation therapy in endometrial cancer, is an excellent overview on the subject. The authors include many photographs or figures of equipment and radiation techniques used in the treatment of patients with uterine cancer.

The final chapter is a well-written review of the role of chemotherapy in patients with advanced endometrial cancer. It includes data on the efficacy of both single-agent and combination drug therapies.

Overall, Endometrial Carcinoma and Precursors is a very good text that presents a focused, relatively concise discussion of endometrial carcinoma. It should be a useful aid to practitioners who manage women with endometrial cancer.

Related Videos
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.